Dr. Nathan Wong is a cardiovascular epidemiologist, specialist in preventive cardiology, and Professor and Director, Heart Disease Prevention Program, Division of Cardiology at the University of California, Irvine, with joint appointments in epidemiology and UCLA and UC Irvine and population health and disease prevention at UC Irvine. He holds MPH and PhD degrees in epidemiology from Yale University and is a fellow of the American College of Cardiology, American Heart Association, National Lipid Association, American Society for Preventive Cardiology (ASPC), and International Academy of Cardiovascular Sciences. He is currently president of the Interamerican Heart Foundation serving Latin America, and is a past president of the ASPC and Pacific Lipid Association. Dr. Wong has primary research interests include subclinical atherosclerosis, where he did some of the original work with coronary calcium and cardiovascular disease over 30 years ago, and epidemiology and management of dyslipidemia and diabetes in relation to cardiovascular disease. He has been an investigator / collaborator with many NIH studies including the Framingham Heart Study, Women’s Health Initiative, and Multiethnic Study of Atherosclerosis, and has conducted numerous clinical trials involving dyslipidemia. He has authored over 400 papers and co-edited seven textbooks, including the Braunwald Companion on Preventive Cardiology and two editions of the ASPC Manual of Preventive Cardiology. He is also on the editorial board of several cardiology and diabetes-related journals, including serving as co-editor-in-chief of the American Journal of Preventive Cardiology. He is also an honorary member of the Academy of Nutrition and Dietetics and recent recipient of the ASPC Joseph Stokes MD Award for lifetime achievement in preventive cardiology and lifetime achievement award in clinical research from the University of California, Irvine School of Medicine.

Contributions

New World of targeted therapies (targets, delivery systems,new molecules) - Discussion and Q&ANew World of targeted therapies (targets and delivery systems and new molecules)90th EAS Congress 2022